Work

First results of the rwe prospective study TEC care (IFM 2023-01) evaluating teclistamab in triple-class exposed relapsed refractory multiple myeloma patients.

Year: 2025
Type: conference-abstract
Source: Blood
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: closed
OpenAlex ID: W4417002296
Cites:
Cited by:
Related to: